Literature DB >> 18974565

Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies.

C Sundaram1, Megha S Uppin, A K Meena.   

Abstract

AIM: Utility of major histocompatibility complex (MHC) Class I antigen immunostaining was studied to differentiate idiopathic inflammatory myopathies from dystrophies.
MATERIALS AND METHODS: Forty muscle biopsies including seven dermatomyositis (DM), six polymyositis (PM), two sporadic inclusion body myositis (sIBM), 20 dystrophies (one Duchenne, three Becker's, four alpha, one gamma sarcoglycanopathy, nine limb girdle, one myotonic and one fascioscapulohumeral muscular dystrophy) and five controls were stained with antibody for MHC Class I antigen (Novocastra clone W6/32 HL 1:100 dilution).
RESULTS: Polymyositis and sIBM showed MHC class I antigen positivity along sarcolemma of single and small groups of muscle fibers. The regenerating fibers in the perifascicular area in DM showed intense cytoplasmic positivity of MHC class I antigen. Muscle fibers in all dystrophies except regenerating fibers and control normal muscle were negative for MHC. Capillaries and lymphocytes were positive controls. There were no false positives in the study.
CONCLUSION: MHC Class I immunostaining can be used as a complementary diagnostic tool for the diagnosis of idiopathic inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974565     DOI: 10.4103/0028-3886.43457

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  7 in total

1.  A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.

Authors:  Lisa Christopher-Stine; Livia A Casciola-Rosen; Grace Hong; Tae Chung; Andrea M Corse; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2010-09

Review 2.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

Review 3.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

4.  The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.

Authors:  Qiu Xu; Qiu-Xiang Li; Fang-Fang Bi; Hui-Qian Duan; Yue-Bei Luo; Huan Yang
Journal:  Clin Rheumatol       Date:  2020-07-15       Impact factor: 2.980

Review 5.  Immunological biomarkers in dermatomyositis.

Authors:  Jeannette M Olazagasti; Timothy B Niewold; Ann M Reed
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

6.  HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.

Authors:  Xiaoming Shu; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

7.  The Assessment of Major Histocompatibility Complex (MHC) Class-I Expression in Different Neuromuscular Diseases.

Authors:  Maher Kurdi; Aysha Alshareef; Ahmed K Bamaga; Zahir T Fadel; Moafaq S Alrawaili; Sahar Hakamy; Fawaz Mohamed; Ahmad R Abuzinadah; Bassam M J Addas; Nadeem Shafique Butt
Journal:  Degener Neurol Neuromuscul Dis       Date:  2021-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.